Mylan Lowers 2017 Expectations on Business Pressure Along With Delayed Launch Timing
We’re not particularly surprised by Mylan’s decision to lower its year-end outlook as EpiPen and the North American generics segment face competitive headwinds and management has shifted expected launches of generic Copaxone and Advair into 2018. As a result, management lowered its year-end revenue outlook to $11.5 billion to $12.5 billion (previously $12.25 billion to $13.75 billion) and adjusted EPS to $4.30 to $4.70 (from $5.15 to $5.55). While the delay of Copaxone and Advair by one year doe...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.